Neuland Laboratories (NSE:NEULANDLAB) Long-Term Debt: ₹1,609 Mil (As of Mar. 2026)


NSE:NEULANDLAB Neuland Laboratories Ltd NSE:NEULANDLAB
92 GF Score
Price ₹18,944.00
GF Value ₹16,537.08
Valuation Modestly Overvalued
! 3 Warning Signs
View Full Analysis

What is Neuland Laboratories Long-Term Debt?

Neuland Laboratories NSE:NEULANDLAB -0.23% 92 Long-Term Debt is ₹1,609 Mil as of Mar. 2026. GuruFocus rates NSE:NEULANDLAB with a GF Score™ of 92/100 and a GF Value™ of ₹16,537.08 (Modestly Overvalued). The stock has 3 warning signs investors should review.

Neuland Laboratories's Long-Term Debt for the quarter that ended in Mar. 2026 was ₹1,609 Mil.

Neuland Laboratories's quarterly Long-Term Debt declined from Sep. 2025 (₹892 Mil) to Dec. 2025 (₹0 Mil) but then increased from Dec. 2025 (₹0 Mil) to Mar. 2026 (₹1,609 Mil).

Neuland Laboratories's annual Long-Term Debt increased from Mar. 2024 (₹449 Mil) to Mar. 2025 (₹907 Mil) and increased from Mar. 2025 (₹907 Mil) to Mar. 2026 (₹1,609 Mil).

Neuland Laboratories  (NSE:NEULANDLAB) Long-Term Debt Explanation

Long-Term Debt is the sum of the carrying values as of the balance sheet date of all long-term debt, which is debt initially having maturities due after one year or beyond the operating cycle, if longer, but excluding the portions thereof scheduled to be repaid within one year or the normal operating cycle, if longer. Long-Term Debt includes notes payable, bonds payable, mortgage loans, convertible debt, subordinated debt and other types of long term debt.

Neuland Laboratories Long-Term Debt Related Terms

Neuland Laboratories Long-Term Debt Historical Data

* Premium members only.

The historical data trend for Neuland Laboratories's Long-Term Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Neuland Laboratories Long-Term Debt Chart

Neuland Laboratories Annual Data
Trend Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24 Mar25 Mar26
Long-Term Debt
Get a 7-Day Free Trial Premium Member Only Premium Member Only 1,042.48 742.46 449.21 907.27 1,609.47

Neuland Laboratories Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Long-Term Debt Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 907.27 0.00 892.24 0.00 1,609.47
NSE:NEULANDLAB
92GF Score
Neuland Laboratories Ltd NSE:NEULANDLAB
Long-Term Debt is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
Frequently Asked Questions Learn more about Long-Term Debt →
What does a Long-Term Debt of ₹1,609 Mil mean?
Neuland Laboratories (NSE:NEULANDLAB) has a Long-Term Debt of ₹1,609 Mil as of Mar. 2026.
Is Neuland Laboratories' Long-Term Debt too high?
Neuland Laboratories' current Long-Term Debt is ₹1,609 Mil. Overall, Neuland Laboratories has a GF Score™ of 92/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Neuland Laboratories' Long-Term Debt compare to ZTS and UTHR?
Neuland Laboratories' Long-Term Debt of ₹1,609 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Long-Term Debt for a Drug Manufacturers company?
A good Long-Term Debt depends on the Drug Manufacturers industry context. However, Long-Term Debt should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Long-Term Debt mean?
A high Long-Term Debt can signal that a stock is expensive relative to its fundamentals. Neuland Laboratories's current Long-Term Debt is ₹1,609 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Neuland Laboratories stock overvalued right now?
Based on GuruFocus' analysis, Neuland Laboratories (NSE:NEULANDLAB) is currently considered Modestly Overvalued. The stock's GF Value™ is ₹16,537.08, compared to a current price of ₹18,944.00 — trading 14.6% above its estimated fair value. The current Long-Term Debt is ₹1,609 Mil. Neuland Laboratories' overall GF Score™ is 92/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Long-Term Debt calculated?
Long-Term Debt is calculated from a company's financial statements. For Neuland Laboratories (NSE:NEULANDLAB), the current Long-Term Debt is ₹1,609 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Neuland Laboratories (NSE:NEULANDLAB) Overvalued in 2026?

Based on GuruFocus' analysis, Neuland Laboratories stock appears to be overvalued. The current stock price of ₹18,944.00 is trading 14.6% above its estimated GF Value™ of ₹16,537.08. GuruFocus considers Neuland Laboratories to be Modestly Overvalued.

Key valuation signals for NSE:NEULANDLAB:

  • Long-Term Debt: ₹1,609 Mil
  • GF Value™: ₹16,537.08 vs. price of ₹18,944.00 (14.6% above fair value)
  • GF Score™: 92/100 with 3 warning signs

No single metric tells the full story. See the NSE:NEULANDLAB stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Neuland Laboratories Business Description

Other Exchanges 524558:India
Address Road No. 82, Jubilee Hills, Plot No. 573A-III, Phoenix IVY Building, 11th Floor (5th Office Level), Hyderabad, TG, IND, 500033
Neuland Laboratories Ltd is engaged in the manufacturing and selling of bulk drugs and caters to both the domestic and international markets. It is an API contract development and manufacturing organization (CDMO), supporting biotechnology and pharmaceutical companies in the design, development, and manufacturing of complex active pharmaceutical ingredients (APIs). The company develops small molecules and peptides for clinical trials and beyond, with the capacity to scale up through every stage of the product lifecycle to commercial manufacturing. Geographically, the group derives maximum revenue from its customers in India, followed by Europe, the USA and North America, and the Rest of the world.
92GF Score

Get the complete analysis for NSE:NEULANDLAB

Long-Term Debt is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

₹18,944.00
Price
₹16,537.08
GF Value